Earlier this month, Raptor Pharmaceutical Corp.'s RP103 (cysteamine bitartrate delayed-release) failed a phase IIb trial in pediatric nonalcoholic steatohepatitis (NASH), but the letdown hasn't ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback